What combination strategies targeting multiple AD pathogenic pathways (Aβ, tau, inflammation, metabolism) demonstrate disease-modifying efficacy in humans?

No current trials investigate combinatorial approaches. Single-target therapies have failed repeatedly, yet the field lacks systematic investigation of synergistic multi-target interventions.